Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression.

Slides:

Advertisements

Similar presentations

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Advertisements

Frances A Shepherd, MD, Rafael Rosell, MD Journal of Thoracic Oncology

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer Yong-Jae Kwon, PhD, Seog Joo Lee, MSc, Jae Soo Koh, MD, PhD, Sung.

Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy

Tumor Cell Repopulation between Cycles of Chemotherapy is Inhibited by Regulatory T- Cell Depletion in a Murine Mesothelioma Model Licun Wu, MD, Zhihong.

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

Carcinoma NOS is a Common Histologic Diagnosis and is Increasing in Proportion Among Non-small Cell Lung Cancer Histologies Sai-Hong Ignatius Ou, MD,

Silencing NKD2 by Promoter Region Hypermethylation Promotes Esophageal Cancer Progression by Activating Wnt Signaling Baoping Cao, MD, PhD, Weili Yang,

Antitumor Efficacy of the Anti-Interleukin-6 (IL-6) Antibody Siltuximab in Mouse Xenograft Models of Lung Cancer Lanxi Song, MS, Matthew A. Smith, PhD,

Group IIa secretory phospholipase expression correlates with group IIa secretory phospholipase inhibition–mediated cell death in K-ras mutant lung cancer.

Upregulation of PD-L1 by EGFR Activation Mediates the Immune Escape in EGFR- Driven NSCLC: Implication for Optional Immune Targeted Therapy for NSCLC Patients.

WT1 Promotes Invasion of NSCLC via Suppression of CDH1

DNMT3B Overexpression by Deregulation of FOXO3a-Mediated Transcription Repression and MDM2 Overexpression in Lung Cancer Yi-Chieh Yang, MS, Yen-An Tang,

Deregulation of SLIT2-Mediated Cdc42 Activity Is Associated with Esophageal Cancer Metastasis and Poor Prognosis Ruo-Chia Tseng, PhD, Jia-Ming Chang,

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Knockdown of secretory phospholipase A2 IIa reduces lung cancer growth in vitro and in vivo Jessica A. Yu, MD, David Mauchley, MD, Howard Li, MD, Xianzhong.

Rafal Dziadziuszko, MD, PhD, Anh T

Genome-Wide Analysis of DNA Methylation and the Gene Expression Change in Lung Cancer Yong-Jae Kwon, PhD, Seog Joo Lee, MSc, Jae Soo Koh, MD, PhD, Sung.

Up-Regulation of RFC3 Promotes Triple Negative Breast Cancer Metastasis and is Associated With Poor Prognosis Via EMT Zhen-Yu He, San-Gang Wu, Fang Peng,

Effective treatment of experimental human endometrial cancers with targeted cytotoxic luteinizing hormone–releasing hormone analogues AN-152 and AN-207

Prognostic Significance of the Number of Lymph Nodes Removed at Lobectomy in Stage IA Non-small Cell Lung Cancer Sai-Hong Ignatius Ou, MD, PhD, Jason.

SC17.02 Lung Cancer in China: Challenges and Perspectives

Expression of LKB1 tumor suppressor in non–small cell lung cancer determines sensitivity to 2-deoxyglucose Landon J. Inge, PhD, Keith D. Coon, PhD, Michael.

Prognostic Significance of C-Reactive Protein and Smoking in Patients with Advanced Non-small Cell Lung Cancer Treated with First-Line Palliative Chemotherapy

Combined Radiotherapy and Anti–PD-L1 Antibody Synergistically Enhances Antitumor Effect in Non–Small Cell Lung Cancer Xiaomei Gong, MD, PhD, Xuefei Li,

Pulmonary Fibroblasts Induce Epithelial Mesenchymal Transition and Some Characteristics of Stem Cells in Non-Small Cell Lung Cancer Yasushi Shintani,

Susan C. Scott, MD, Nathan A. Pennell, MD, PhD

Uterine luminal epithelium–specific proline-rich acidic protein 1 (PRAP1) as a marker for successful embryo implantation Honglu Diao, Ph.D., Shuo Xiao,

Inhibition of phosphatidylinositol 3-kinase/Akt and histone deacetylase activity induces apoptosis in non–small cell lung cancer in vitro and in vivo

Combining the Multitargeted Tyrosine Kinase Inhibitor Vandetanib with the Antiestrogen Fulvestrant Enhances Its Antitumor Effect in Non-small Cell Lung.

Ellen M. Schultz, MS, Gerard A. Silvestri, MD, MS, Michael K

The Autophagy Inhibitor Chloroquine Overcomes the Innate Resistance of Wild-Type EGFR Non-Small-Cell Lung Cancer Cells to Erlotinib Yiyu Zou, PhD, Yi-He.

Chronic pulmonary artery occlusion increases alveolar fluid clearance in rats Zheng Wang, MD, Jin Xu, MD, Gang Ma, MD, Motoyasu Sagawa, MD, PhD, Miyako.

Zoledronic Acid Produces Antitumor Effects on Mesothelioma Through Apoptosis and S- Phase Arrest in p53-Independent and Ras prenylation-Independent Manners

Hepatocyte Growth Factor Induces Resistance to Anti-Epidermal Growth Factor Receptor Antibody in Lung Cancer Tadaaki Yamada, MD, PhD, Shinji Takeuchi,

Nicotine Induces Resistance to Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor by α1 Nicotinic Acetylcholine Receptor–Mediated Activation in.

Inhibiting MDM2-p53 Interaction Suppresses Tumor Growth in Patient-Derived Non– Small Cell Lung Cancer Xenograft Models Josephine Hai, PhD, Shingo Sakashita,

Correlation Between Polymorphisms of the Reduced Folate Carrier Gene (SLC19A1) and Survival After Pemetrexed-Based Therapy in Non-small Cell Lung Cancer:

AT-101, a Pan-Bcl-2 Inhibitor, Leads to Radiosensitization of Non-small Cell Lung Cancer Luigi Moretti, MD, Bo Li, MD, Kwang Woon Kim, PhD, Heidi Chen,

MicroRNA-101 Exerts Tumor-Suppressive Functions in Non-small Cell Lung Cancer through Directly Targeting Enhancer of Zeste Homolog 2 Ji-guang Zhang,

Tumor Cell Content for Selection of Molecular Techniques for T790M EGFR Mutation Detection in Non-small Cell Lung Cancer Nathalie Prim, Elisabeth Quoix,

Pretreatment Quality of Life Is an Independent Prognostic Factor for Overall Survival in Patients with Advanced Stage Non-small Cell Lung Cancer Yingwei.

Lung cancer cell invasion and expression of intercellular adhesion molecule-1 (ICAM-1) are attenuated by secretory phospholipase A2 inhibition Jessica.

Mediastinal Lymph Node Examination and Survival in Resected Early-Stage Non– Small-Cell Lung Cancer in the Surveillance, Epidemiology, and End Results.

Jeffrey Bradley, MD, Issam El Naqa, PhD Journal of Thoracic Oncology

Apelin Expression in Human Non-small Cell Lung Cancer: Role in Angiogenesis and Prognosis Judit Berta, MS, Istvan Kenessey, MD, Judit Dobos, PhD, Jozsef.

IL-6 Secreted from Cancer-Associated Fibroblasts Mediates Chemoresistance in NSCLC by Increasing Epithelial-Mesenchymal Transition Signaling Yasushi.

Antiestrogen Fulvestrant Enhances the Antiproliferative Effects of Epidermal Growth Factor Receptor Inhibitors in Human Non–Small-Cell Lung Cancer Edward.

Christina I. Selinger, PhD, Wendy A

Socioeconomic Status Is Associated with Depressive Severity Among Patients with Advanced Non–Small-Cell Lung Cancer: Treatment Setting and Minority Status.

miR-124 Inhibits Lung Tumorigenesis Induced by K-ras Mutation and NNK

LAG-3 Protein Expression in Non–Small Cell Lung Cancer and Its Relationship with PD- 1/PD-L1 and Tumor-Infiltrating Lymphocytes Yayi He, MD, PhD, Hui.

PD-L1 as a Companion Biomarker for Immune Checkpoint Inhibitors in NSCLC: Should RNA ISH (RISH) Be Considered? Steven G. Gray, PhD Journal of Thoracic.

Daniel Morgensztern, MD, Boone Goodgame, MD, Maria Q

Histone Deacetylase Inhibitor Romidepsin Enhances Anti-Tumor Effect of Erlotinib in Non-small Cell Lung Cancer (NSCLC) Cell Lines Wei Zhang, PhD, Michael.

Nicotinamide Phosphoribosyltransferase: A Potent Therapeutic Target in Non-small Cell Lung Cancer with Epidermal Growth Factor Receptor-Gene Mutation

Chadrick E. Denlinger, MD, Brian K. Rundall, DO, Michael D

Tumor-Stroma Ratio Is an Independent Predictor for Survival in Esophageal Squamous Cell Carcinoma kai Wang, MD, Wei Ma, MD, Jianbo Wang, MD, Liang Yu,

Tumor Response Kinetics after Schedule-Dependent Paclitaxel Chemoradiation Treatment for Inoperable Non-small Cell Lung Cancer: A Model for Low-Dose.

SHOX2 DNA Methylation Is a Biomarker for the Diagnosis of Lung Cancer in Plasma Christoph Kneip, PhD, Bernd Schmidt, MD, Anke Seegebarth, Sabine Weickmann,

Trends in Stage Distribution for Patients with Non-small Cell Lung Cancer: A National Cancer Database Survey Daniel Morgensztern, MD, Shean Huey Ng,

Phase II Study of Perioperative Chemotherapy with Cisplatin and Pemetrexed in Non– Small-Cell Lung Cancer Grace K. Dy, MD, Paul N. Bogner, MD, Wei Tan,

Gefitinib Enhances Cytotoxicities of Antimicrotubule Agents in Non–Small-Cell Lung Cancer Cells Exhibiting No Sensitizing Epidermal Growth Factor Receptor.

IGF-1 regulation of type II collagen and MMP-13 expression in rat endplate chondrocytes via distinct signaling pathways M. Zhang, Ph.D., Q. Zhou, M.D.,

Surveillance Epidemiology and End Results Evaluation of the Role of Surgery for Stage I Small Cell Lung Cancer James B. Yu, MD, Roy H. Decker, MD, PhD,

Overexpression of CRM1: A Characteristic Feature in a Transformed Phenotype of Lung Carcinogenesis and a Molecular Target for Lung Cancer Adjuvant Therapy

A Review of First-Line Treatment for Small-cell Lung Cancer

Mark A. Socinski, MD Journal of Thoracic Oncology

Molecular Therapy - Nucleic Acids

Presentation transcript:

Improved Response to nab-Paclitaxel Compared with Cremophor-Solubilized Paclitaxel is Independent of Secreted Protein Acidic and Rich in Cysteine Expression in Non-Small Cell Lung Cancer Huanjie Shao, PhD, Haikuo Tang, MD, PhD, Oreste E. Salavaggione, MD, Chunrong Yu, PhD, Bonnie Hylander, PhD, Wei Tan, MA, Elizabeth Repasky, PhD, Alex A. Adjei, MD, PhD, Grace K. Dy, MD Journal of Thoracic Oncology Volume 6, Issue 6, Pages 998-1005 (June 2011) DOI: 10.1097/JTO.0b013e318217b739 Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 1 Representative examples of methylation-specific PCR assay for SPARC in NSCLC cell lines and NSCLC xenografts. H460 cells were treated with DEC (5 μM) in vitro for 3 days. PCR products were visualized on 1.5% agarose gels. w/, treated with; Me, methylated; UM, unmethylated; PCR, polymerase chain reaction; SPARC, secreted protein acidic and rich in cysteine; NSCLC, non-small cell lung cancer; DEC, 5-Aza-2′-deoxycytidine. Journal of Thoracic Oncology 2011 6, 998-1005DOI: (10.1097/JTO.0b013e318217b739) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 2 Western blot showing that SPARC expression in xenografts and NSCLC cell lines is up-regulated on treatment with DEC. A, NSCLC cell lines A549, H460, and H157 were treated with 5 μM DEC for 3 days in vitro and then harvested for RT-PCR. B, PD NSCLC xenografts and H460 xenografts treated with or without DEC 1.5 mg/kg/d, and xenografts were harvested for SPARC expression analysis. GAPDH were used as the endogenous control. w/, treated with; SPARC, secreted protein acidic and rich in cysteine; PD NSCLC, patient-derived non-small cell lung cancer; DEC, 5-Aza-2′-deoxycytidine; GAPDH, glyceraldehyde-3-phosphate dehydrogenase; RT-PCR, real-time polymerase chain reaction. Journal of Thoracic Oncology 2011 6, 998-1005DOI: (10.1097/JTO.0b013e318217b739) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 3 Efficacy of ABX compared with taxol in PD NSCLC xenografts. SCID mice bearing SPARC-positive xenografts (NSCLC_16372) (A), SPARC-intermediate xenografts (NSCLC_15946) (B), or SPARC-negative xenografts, NSCLC_16465 (C) and NSCLC_16591 (D), were treated with vehicle, equitoxic dose of taxol (13.4 mg/kg), or ABX (30 mg/kg). The overall antitumor efficacy of drugs was measured as tumor volumes every 2 to 3 days. The error bars represented the standard error of the mean. PD NSCLC, patient-derived non-small cell lung cancer; SCID, severe combined immunodeficiency; SPARC, secreted protein acidic and rich in cysteine. Journal of Thoracic Oncology 2011 6, 998-1005DOI: (10.1097/JTO.0b013e318217b739) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 4 Enhanced antitumor efficacy of taxol and ABX by pretreatment with DEC in SPARC-negative xenografts. A–C, SCID mice bearing SPARC-negative xenografts, NSCLC_16325 (A), NSCLC_16384 (B), or H460 (C), were administered with DEC (1.5 mg/kg), taxol (13.4 mg/kg) or ABX (30 mg/kg) alone or the combination of DEC and taxol or DEC and ABX. The overall antitumor efficacy of drugs was measured as tumor volumes every 2 to 3 days. The error bars represented the standard error of the mean. DEC, 5-Aza-2′-deoxycytidine; SPARC, secreted protein acidic and rich in cysteine; NSCLC, non-small cell lung cancer. Journal of Thoracic Oncology 2011 6, 998-1005DOI: (10.1097/JTO.0b013e318217b739) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions

FIGURE 5 Cell death rate analysis with NSCLC cell lines A549 and H460 in vitro showing additive antitumor activity of ABX or taxol by pretreatment with DEC. A and C, results of H460 cells treated with escalating concentrations of ABX or taxol after DEC 5μM pretreatment. B and D, results of A549 cells treated with escalating concentrations of ABX or taxol after DEC 5 μM pretreatment. Treated cells were harvested for cell death rates assay (*p < 0.05, compared with ABX or taxol treatment alone). Data represents mean ± standard deviation of three independent experiments. NSCLC, non-small cell lung cancer; DEC, 5-Aza-2′-deoxycytidine. Journal of Thoracic Oncology 2011 6, 998-1005DOI: (10.1097/JTO.0b013e318217b739) Copyright © 2011 International Association for the Study of Lung Cancer Terms and Conditions